
Loading, please wait...

Loading, please wait...

Clinicians frequently face therapeutic uncertainties when optimizing pharmacotherapy in HFpEF and mildly reduced ejection fraction. Although guideline recommendations continue to evolve, isolating the independent contributions of individual medications remains challenging. Most randomized trials evaluate therapies against heterogeneous background regimens. Consequently, standard network meta-analyses struggle to separate true additive treatment effects from polypharmacy.
To address this gap, researchers conducted a component network meta-analysis of phase three and four randomized trials. Specifically, investigators searched major medical databases, including MEDLINE, Embase, and Cochrane, through early 2026. They analyzed twenty-four trials and five secondary publications involving patients with ejection fractions exceeding forty percent. Importantly, the primary network comprised ten pivotal trials encompassing twelve distinct therapeutic regimens.
Through this additive approach, researchers assessed composite cardiovascular mortality and initial heart failure hospitalizations. Furthermore, investigators systematically evaluated evidence certainty using established grading frameworks. Because these patients present with complex comorbidities, identifying genuine disease-modifying components offers substantial clinical value.
The meta-analysis demonstrated that sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists provide the most consistent clinical benefits. Specifically, SGLT-2 inhibitors achieved an incremental hazard ratio of 0.80, with confidence intervals spanning from 0.74 to 0.88. Mineralocorticoid receptor antagonists similarly delivered a significant risk reduction, demonstrating an incremental hazard ratio of 0.89. In addition, extensive sensitivity analyses confirmed the stability of both drug classes across diverse clinical scenarios.
Notably, fewer heart failure hospitalizations primarily drove these observed clinical improvements. SGLT-2 inhibitors displayed the highest statistical precision among all evaluated classes, underscoring their dependable decongestive and cardio-renal protective properties. However, their statistical significance diminished when investigators restricted the analysis strictly to patients with ejection fractions of fifty percent or higher. This boundary finding suggests that therapeutic responsiveness may subtly decline as systolic function normalizes.
Nevertheless, both drug classes represent foundational components of contemporary outpatient care. Clinicians can confidently prescribe SGLT-2 inhibitors and mineralocorticoid receptor antagonists to reduce hospital admissions in symptomatic individuals. Therefore, cardiologists should prioritize these agents when treating patients with preserved or mildly reduced function.
Angiotensin receptor-neprilysin inhibitors also exhibited a favorable initial signal in the primary component model. Specifically, ARNis generated an incremental hazard ratio of 0.82, with confidence intervals spanning from 0.68 to 0.99. This finding aligns with physiological expectations regarding neprilysin inhibition, which augments endogenous natriuretic peptides and promotes vasodilation. Furthermore, clinical trials show that sacubitril/valsartan effectively reduces filling pressures and improves functional status.
However, the statistical benefit of ARNis proved sensitive to background medical therapy and trial selection. For instance, the incremental advantage disappeared when investigators applied stricter background therapy thresholds requiring at least sixty percent guideline coverage. In addition, restricting the analysis to contemporary trials attenuated the observed significance. These fluctuations suggest that earlier trials without modern background therapies may have exaggerated the unique additive impact of ARNis.
Consequently, clinicians should interpret the incremental contribution of ARNis within the context of comprehensive therapy. While ARNis remain valuable for managing hypertension, their additive role over optimized baseline care requires careful patient selection. Physicians must evaluate blood pressure tolerance, renal function, and concurrent medications before initiating ARNi therapy.
Recent clinical investigations have highlighted incretin mimetics as promising metabolic therapies for patients with preserved ejection fraction and obesity. In this network meta-analysis, pooled incretin therapies, including semaglutide and tirzepatide, demonstrated an incremental hazard ratio of 0.69. This point estimate suggests a substantial thirty-one percent reduction in composite cardiovascular events. Moreover, incretin therapies improve body weight, systemic inflammation, exercise capacity, and metabolic parameters in obesity-related heart failure phenotypes.
Despite these encouraging preliminary metrics, the authors rated the overall certainty of evidence as low. Because the primary network contained relatively few incretin trials, the findings proved highly sensitive to trial selection and model specifications. In addition, the sparse analytical network prevented robust evaluation of statistical interactions between incretins and standard neurohormonal blockers. Therefore, clinicians cannot yet conclude whether incretins provide synergistic disease modification or act primarily through glycemic and weight control.
Nonetheless, incretin-based medications represent an exciting therapeutic frontier. Ongoing randomized trials will clarify their precise role in reducing hard cardiovascular endpoints. Until larger definitive networks emerge, clinicians should view incretins as valuable adjuncts for cardiometabolic optimization rather than established standalone therapies.
A striking finding from this component network meta-analysis is the universal lack of significant mortality reduction. None of the evaluated pharmacological classes independently reduced cardiovascular death in patients with mildly reduced or preserved ejection fraction. Even therapies that significantly curtailed heart failure hospitalizations failed to influence hard survival metrics. This limitation highlights the distinct pathophysiology of higher ejection fraction heart failure compared to classic heart failure with reduced ejection fraction.
In HFpEF, non-cardiovascular comorbidities significantly drive overall disease burden and patient mortality. Conditions like renal disease, hypertension, diabetes, atrial fibrillation, and obesity accelerate vascular stiffness and end-organ dysfunction. Consequently, isolated neurohormonal antagonism cannot fully counteract systemic multiorgan decline. While medications effectively lower left ventricular filling pressures and prevent decompensation, they rarely reverse established myocardial fibrosis or systemic microvascular dysfunction.
Ultimately, these findings emphasize that clinicians must adopt an individualized treatment strategy. Rather than prescribing rigid multidrug combinations, physicians should prioritize SGLT-2 inhibitors and mineralocorticoid receptor antagonists to minimize hospitalizations. In addition, practitioners must aggressively treat underlying metabolic and hypertensive conditions. Combining proven decongestive components with lifestyle and comorbidity management remains the most effective clinical approach for enhancing patient quality of life.
Sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists provide the most consistent incremental benefits in patients with preserved ejection fraction. Both drug classes significantly reduce the hazard of heart failure hospitalizations across diverse clinical scenarios. Furthermore, SGLT-2 inhibitors exhibit the highest statistical precision among evaluated therapies. Although their incremental efficacy modestly diminishes in patients with ejection fractions above fifty percent, they remain foundational components of modern heart failure therapy.
Current clinical evidence shows that no pharmacological class significantly reduces cardiovascular mortality in patients with heart failure and ejection fractions above forty percent. Unlike heart failure with reduced ejection fraction, where neurohormonal blockers extend survival, HFpEF mortality stems heavily from non-cardiovascular comorbidities and systemic vascular stiffness. Consequently, therapeutic benefits primarily manifest as fewer hospital admissions and improved functional status rather than prolonged survival. Clinicians should emphasize comprehensive comorbidity control alongside decongestive therapy.
Incretin mimetics, such as semaglutide and tirzepatide, show substantial potential for reducing composite cardiovascular events in patients with obesity-related heart failure phenotypes. They produce notable weight loss, reduce systemic inflammation, and enhance exercise tolerance. However, evidence remains low-certainty because available trials are limited and highly sensitive to analytical models. Therefore, clinicians should currently utilize incretins to optimize metabolic comorbidities and obesity rather than viewing them as replacement heart failure therapies.
Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment and should not be used as a substitute for professional healthcare guidance. While we strive to present accurate and current evidence-based clinical information, medical research is continually evolving. Readers should verify clinical choices against current medical standards and consult with a licensed healthcare provider before making medical decisions or changing treatment plans. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A systematic review and component network meta-analysis evaluated the incremental benefits of drug classes in HFmrEF and HFpEF. SGLT-2 inhibitors and MRAs provided the most robust reductions in heart failure hospitalizations, while mortality benefits remained elusive across all investigated drug classes.
Today

A landmark study reveals that physiologic subtypes of gestational glucose intolerance, including insulin resistance and insulin deficiency, independently raise long-term risks of maternal prediabetes and diabetes, underscoring the urgent need for structured postpartum surveillance.
Today

Groundbreaking experimental research demonstrates that CX3CR1 deficiency significantly attenuates endometriotic lesion growth by suppressing pro-repair M2 macrophage polarization. This discovery identifies the CX3CL1-CX3CR1 chemokine axis as a promising non-hormonal target for managing chronic endometriosis.
Today

A meta-analysis of 19 studies reveals that 69% of ophthalmologists suffer from work-related musculoskeletal disorders. Slit lamps, microscopes, and high surgical loads cause severe cervical and lumbar strain, underscoring the urgent need for ergonomic workstations, micro-breaks, and institutional reforms.
Today

Mayo Clinic trials and real-world datasets show GLP-1 receptor agonists improve left ventricular remodeling, reduce intracardiac filling pressures, decrease hospitalizations by 34%, and lower geriatric fall risks in patients with obesity and heart failure, delivering notable clinical and economic benefits.
Today